Enrollment in Affordable Care Act plans is unlikely to increase in 2019; the outgoing Republican governor of Idaho has announced his support for expanding Medicaid; a new state audit has found that California spent $4 billion on people who were ineligible for Medi-Cal, the state’s Medicaid program.
From 2017 to 2018, enrollment in Affordable Care Act (ACA) plans was mostly unchanged, and it is unlikely that enrollment will increase in 2019. According to The Hill, experts expect that the expansion of less expensive plans that don’t meet the ACA’s requirements and the repeal of the penalty for people who don’t have coverage will likely cause more people to leave the exchanges. Individuals who do not qualify for federal subsidies are most likely to drop out of the exchanges.
The outgoing Republican governor of Idaho has announced his support for expanding Medicaid. Expansion will be available as a ballot measure for Idahoans to vote on next week and could cover up to 62,000 people, according to The Washington Post. Governor C.L. “Butch” Otter has said that expanding the program will help keep rural hospitals and clinics open. The Democratic gubernatorial candidate also supports the measure and the Republican gubernatorial candidate said he will support the outcome of the ballot measure vote.
A new state audit has found that California spent $4 billion on people who were ineligible for Medi-Cal, the state’s Medicaid program. The Los Angeles Times reported that 453,000 beneficiaries were marked as eligible in the state’s system but were not in the counties’ systems, which may mean they had not been eligible. The reason for those individuals not being eligible could be because they died, moved, or made enough money that they no longer qualified for the program. Despite the discrepancy, the state paid $4 billion to health plans and doctors for those patients’ care over 4 years.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More